Frontier of Therapy Series: “Training” Immunity to Fight Cancer — CAR-T at a Glance (From Beginner to Expert) | A5: What Is In Vivo CAR? “Making CAR Cells Inside the Body” Explained Simply [Beginner]

Prefer the beginner overview first?
→ A0: What is CAR-T therapy? The big picture + index
→ A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an “Immune Reset” Concept)

“In vivo CAR at a glance: dose → in-body CAR expression → transient vs durable effects”

The short answer: in vivo CAR aims to build CAR cells inside the body

Conventional CAR-T is made outside the body (collect cells → engineer/expand → infuse).
In vivo CAR aims to deliver the “instructions” so that CAR cells are generated inside the patient.

Think:

• Conventional CAR-T: manufacture outside → ship back in
• In vivo CAR: deliver instructions → manufacture at the point of care (in vivo)

The motivation is to remove bottlenecks in time, infrastructure, and access.

1) Why in vivo CAR is being pursued: removing classic CAR-T bottlenecks

Ex vivo CAR-T often implies:

• manufacturing turnaround time and logistics
• specialized sites and operational complexity
• high cost and limited scalability
• patient-by-patient manufacturing constraints

In vivo CAR tries to move closer to an “off-the-shelf dosing” model.

2) Three high-level implementation patterns

Pattern A: deliver mRNA (e.g., LNP) → transient CAR expression

mRNA delivery can yield time-limited CAR expression, which can be attractive for safety and controllability.

Pattern B: deliver DNA (e.g., viral vectors) → potentially longer expression

Durability may improve, but long-term safety and follow-up become more central.

Pattern C: in vivo gene editing/integration (future-facing)

High specificity is required; could become “true in vivo cell therapy” if solved.

3) Where the field is now: academic validation + clinical momentum

Academic proof-of-concept (Science, 2025)

A Science paper reported in vivo CAR-T generation via CD8-targeted LNP delivering anti-CD19 CAR mRNA.

Clinical momentum (Capstan, 2025)

Capstan announced initiation of a Phase 1 trial for CPTX2309, an in vivo anti-CD19 CAR-T using targeted LNPs, emphasizing tunable/dose-dependent CAR expression for B-cell–mediated autoimmune disorders.

4) The upside (what could be meaningfully better)

• faster access (less manufacturing delay)
• broader reach (less site dependence)
• repeatability (especially for mRNA approaches)
• better cost structure vs individualized manufacturing (in principle)

5) The key risks (what must be solved)

Risk 1: delivery specificity (off-target transfection)

Targeted delivery is the core problem—hence CD8-targeted LNP concepts.

Risk 2: controllability (how to avoid runaway activity)

Dose, interval, and variability across patients must be engineered into protocols; transient expression helps but is not a full solution.

Risk 3: long-term safety and follow-up

Gene-modified therapy logic brings long-term follow-up expectations; FDA LTFU guidance frames this landscape.

6) A simple way to read in vivo CAR news (4 checks)

1. What is delivered? (mRNA/LNP vs DNA/vector)
2. Which cells are targeted?
3. Is expression transient or durable?
4. What is the safety/control and follow-up design?

Next (B5)

B5 will cover implementation details: delivery engineering, dose-control logic, safety mechanisms, and regulatory/CMC implications.

References

Science (2025): CD8-targeted LNP in vivo CAR-T generation.
Capstan (2025): CPTX2309 Phase 1 initiation (tLNP; tunable CAR expression).
Trends in Biotechnology (2025): in vivo CAR technology review.
FDA (2020): Long-term follow-up guidance for gene therapy products.